Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and cool autumn breezes circulating the Pharmalot campus. Moreover, our official mascot is happily snoozing in a corner, which makes it easier to tend to the matters at hand. Such as? Of course, this includes brewing cups of stimulation and foraging for interesting items. Speaking of which, here are a few to get you started. Hope your day goes well and you conquer the world. Meanwhile, please do stay in touch. …

The Covid-19 pandemic has driven nearly 37 million people into extreme poverty and reversed two decades of progress in vaccinating children against once-common childhood diseases, The Wall Street Journal writes, citing a new report by the Bill & Melinda Gates Foundation. The number of people living in extreme poverty globally has risen 7.1% so far this year in the pandemic. The pandemic has also pushed the percentage of children who are vaccinated against diphtheria, tetanus, and pertussis down to the level it was last at in 2000

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • And in regards to Trump’s executive order on “most favored nation”, it seems like he has exceeded his authority. Laws are not made by the executive branch but by the legislative branch of our government. I would like to see some lowering of drug costs. We all agree on that. I just don’t think that Trump can act like a king and post an edict to the wall.

  • I agree with Bill Gates. What is lacking is a concerted effort by the NIH to coordinate research programs. At the onset of the epidemic, back in March, the NIH should have “vetted” some 600 hospitals or hospital groups, readying them for clinical trials. They should have prepared some 300 outpatient clinics whether associated with a hospital or not. Then coordinate a research idea among 200 or 300 hospitals, to get a study started and completed rapidly. Rather than a dozen US hospitals testing Hydroxychloroquine as a preventative in household contacts or hospital workers, and having 150 patients on a given study, have one study of 800 paricipants over 50 hospitals an complete enrollment in a matter of three weeks. (Not that this study would be positive, but such a study would give a quick answer). It would also allow exploration of Remdesivir for outpatient ambulatory patients. It would allow a quick study of Favipiravir in outpatients (a drug like Rodney Dangerfield “gets no respect” in the US.). It would then allow rapid evaluation of combination antivirals, such as Remdes and Favi, or Remdes and MK4482 (EIDD-2801). Not to mention testing of various anti-inflammatories and anti-virals. I recognize the immense effort that would have to take place for this to happen, but think of how much further alone we would be now. If only the NIH would take charge, show leadership, coordinate efforts. It hasn’t happened and that saddens me.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy